Delivery Order SPE2DR25D1202-SPE2DR26F74CE
- Not listed
- On January 6, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $1,460.13 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 MG tablets (30-count units). This firm fixed-price, non-set-aside contract is scheduled for completion by January 28, 2026, with performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which...
- The Defense Logistics Agency awarded a delivery order valued at $17,521.56 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets (30-count units) under a firm fixed price contract. This non-set-aside award, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, represents a routine pharmaceutical procurement through the federal medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, executed performance from its...
- The Defense Logistics Agency awarded a $1,385.52 delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) under a firm fixed-price contract. The award was made on August 6, 2025, with an ultimate completion date of August 27, 2025, and does not utilize a set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child contract under the...
- The Defense Logistics Agency awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units), with an ultimate completion date of August 25, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) with a ceiling value of $4,156.56 under a firm fixed-price contract. This non-competitive delivery order, issued on June 2, 2025, represents a single pharmaceutical procurement to be fulfilled by June 24, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,920.26 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) on January 2, 2026, with completion expected by January 26, 2026. This firm fixed price, non-set-aside contract represents a routine pharmaceutical procurement under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The delivery order will be fulfilled from the vendor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $8,313.12 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of ORGOVYX 120 mg tablets (30-count unit of use packaging). This firm fixed-price contract, with a completion date of September 25, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made through open competition...
- The Defense Logistics Agency awarded a $8,313.12 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of ORGOVYX 120 mg tablets (30-count unit dose) with an ultimate completion date of October 16, 2025. The contract is non-competitive with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,460.13 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-unit package) on October 22, 2025, with an ultimate completion date of November 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a ceiling value of $1,460.13. This competitive delivery order, issued on December 30, 2025, with an ultimate completion date of January 22, 2026, utilizes firm fixed pricing and carries no set-aside designation. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F74CEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,460.13 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) on January 16, 2026, with an ultimate completion date of February 9, 2026. This is a firm fixed-price, non-set-aside contract with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.99 million through December 31, 2031, which serves as the primary vehicle for supplying pharmaceutical products and medical supplies to military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, competes on a full and open basis for federal medical procurement contracts and demonstrates extensive capability in fulfilling diverse pharmaceutical requirements across multiple therapeutic domains. The company's contract portfolio with DLA includes delivery of brand-name and generic medications, vaccines, and specialized medical supplies supporting military treatment facilities and veteran healthcare programs worldwide. This specific delivery order for ORGOVYX, an oncology medication, exemplifies the company's role as a critical vendor in the federal medical supply chain serving the Department of Defense's healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 1/15/26 |